Ketorolac Tromethamine Injection, Solution
Product Images NDC 51662-1594

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Ketorolac Tromethamine (NDC 51662-1594). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pouch Labeling (51662 1594 2 Pouch Label)

KETOROLAC TROMETHAMINE injection, USP, 30 mg/mL in 1 mL single-dose vial. Label includes NDC 51662-1594-2, lot and expiration date, and states intramuscular or intravenous use. It lists inactive ingredients and storage instructions. Manufacturer is HF Acquisition Co., LLC, Mukilteo, WA.*

FDA Label Image

Case Labeling (51662 1594 3 Case Label)

Label for Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL single dose vials in a case of 25. The label includes NDC 51662-1594-3, lot and expiry information, manufacturer HF Acquisition Co LLC, Mukilteo, WA. It specifies intramuscular or intravenous use and lists inactive ingredients and storage instructions.*

FDA Label Image

Rfid Labeling (51662 1594 3 Rfid Labeling)

KETOROLAC TROMETHAMINE injection, solution for intramuscular use, 30 mg/mL. The label includes the product name, dosage form, strength, and specifies it is for prescription use only. The label is distributed by HF Acquisition Co LLC, DBA HealthFirst.*

FDA Label Image

Vial Label (63323 162 00 Ketorolac Vial Label (1))

Label for Ketorolac Tromethamine injection, USP, 30 mg per mL. The single-dose vial label indicates it is for intramuscular or intravenous use and includes a barcode along with lot and expiration information. The label also carries the Fresenius Kabi branding.*

FDA Label Image

Adverse 1 (Adverse 1)

A data table listing gastrointestinal (GI) experiences, such as abdominal pain, constipation/diarrhea, dyspepsia, flatulence, GI fullness, GI ulcers, gross bleeding/perforation, heartburn, nausea, stomatitis, and vomiting. It also lists other experiences including abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating.*

FDA Label Image

Adverse 2 (Adverse 2)

A data table presenting the incidence of clinically serious gastrointestinal bleeding related to age, total daily dose, and history of GI perforation, ulcer, or bleeding (PUB) after up to 5 days of treatment with Ketorolac Tromethamine Injection. It separates adult patients into those without and with a history of PUB, showing percentages of GI bleeding incidence across different age groups and total daily doses of Ketorolac Tromethamine Injection.*

FDA Label Image

Boxed Warning (Boxed Warning)

Drug Facts panel for Ketorolac Tromethamine 30 mg/mL injection solution by HF Acquisition Co LLC. The panel outlines warnings, contraindications, cardiovascular and gastrointestinal risks, bleeding risk, precautions for special populations, and dose/administration guidelines for intramuscular use only.*

FDA Label Image

Clinical 1 (Clinical 1)

A data table presenting approximate average pharmacokinetic parameters (mean ± SD) for Ketorolac Tromethamine following oral, intramuscular, and intravenous bolus doses at various strengths (10 mg to 60 mg). The table includes bioavailability, Tmax, Cmax, Cmin, Cavg, and volume of distribution (Vβ) values for each dosage and administration route.*

FDA Label Image

Clinical 2 (Clinical 2)

A data table titled 'The Influence of Age, Liver and Kidney Function, on the Clearance and Terminal Half-life of Ketorolac Tromethamine (INTRAMUSCULAR and ORAL) in Adult Populations'. It presents total clearance (in L/h/kg) and terminal half-life (in hours) data for different subject types, including normal subjects, healthy elderly subjects, patients with hepatic dysfunction, renal impairment, and renal dialysis patients, with mean values and ranges for both intramuscular and oral administration.*

FDA Label Image

Logo (Logo)

FDA Label Image

Structure (Structure)

Chemical structure of ketorolac tromethamine shown as two connected molecular diagrams representing ketorolac and tromethamine components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.